300146:SZSEBy-health Co., Ltd. Class A Analysis

Byhealth’s shares are trading at ¥9.82, comfortably below the 20‑day SMA of ¥9.72 and the 50‑day SMA of ¥10.28, indicating short‑term weakness. The MACD histogram has turned positive (0.06) while the MACD line sits above its signal, suggesting a nascent bullish momentum. Support at ¥9.34 is holding, and the nearest resistance at ¥10.09 leaves roughly a 30% upside to the DCF‑derived fair value of ¥10.72. The stock’s beta of 0.17 and a volatility of 25% point to a relatively calm price profile. A dividend yield of 4.6% with an 81.8% payout is attractive for income‑focused investors. However, the broader market sentiment is in “Extreme Greed” (fear‑greed index 91.46), which could accelerate price moves.
Fundamentals show a 4.3% revenue growth and a healthy gross margin of 68%, underscoring a resilient business model. With cash of ¥5.93 bn and debt under ¥1 bn, the balance sheet is strong and supports the current dividend. ROE of 6.5% and forward P/E of 16.8 suggest modest profitability but ample room for valuation expansion. The consumer‑defensive packaged‑food sector is typically low‑risk, though regulatory scrutiny of supplements adds a medium‑level concern. Geographic concentration in China introduces medium‑level exposure to domestic economic cycles. Taken together, the undervalued price, solid cash generation, and defensive positioning justify a buy stance across horizons.